{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:20:52Z","timestamp":1793748052341,"version":"4.6.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67197-3","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T02:06:47Z","timestamp":1764986807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting TNK2\/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Chao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weishuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9318-0079","authenticated-orcid":false,"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3422-2763","authenticated-orcid":false,"given":"Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3435-6550","authenticated-orcid":false,"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2255-6504","authenticated-orcid":false,"given":"Peiqing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9468-9168","authenticated-orcid":false,"given":"Chongbiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9442-619X","authenticated-orcid":false,"given":"Antao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-1730","authenticated-orcid":false,"given":"Jihui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"67197_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"67197_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/JP9.0000000000000093","volume":"5","author":"Z-H Xu","year":"2022","unstructured":"Xu, Z.-H., Wang, W.-Q., Lou, W.-H. & Liu, L. Insight of pancreatic cancer: recommendations for improving its therapeutic efficacy in the next decade. J. Pancreatol. 5, 58\u201368 (2022).","journal-title":"J. Pancreatol."},{"key":"67197_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01151-3","volume":"19","author":"JQ Fan","year":"2020","unstructured":"Fan, J. Q. et al. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Mol. Cancer 19, 32 (2020).","journal-title":"Mol. Cancer"},{"key":"67197_CR4","doi-asserted-by":"publisher","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","volume":"36","author":"HM Kolbeinsson","year":"2023","unstructured":"Kolbeinsson, H. M., Chandana, S., Wright, G. P. & Chung, M. Pancreatic cancer: a review of current treatment and novel therapies. J. Invest. Surg. 36, 2129884 (2023).","journal-title":"J. Invest. Surg."},{"key":"67197_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1200\/JCO.22.02272","volume":"41","author":"SL Topalian","year":"2023","unstructured":"Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 41, 943\u2013954 (2023).","journal-title":"J. Clin. Oncol."},{"key":"67197_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"67197_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1200\/JCO.22.02270","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 41, 715\u2013723 (2023).","journal-title":"J. Clin. Oncol."},{"key":"67197_CR8","doi-asserted-by":"publisher","first-page":"102502","DOI":"10.1016\/j.ctrv.2022.102502","volume":"113","author":"F Dayyani","year":"2023","unstructured":"Dayyani, F., Macarulla, T., Johnson, A. & Wainberg, Z. A. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: a systematic literature review. Cancer Treat. Rev. 113, 102502 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"67197_CR9","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","volume":"5","author":"EM O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1431\u20131438 (2019).","journal-title":"JAMA Oncol."},{"key":"67197_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"Cancer Genome Atlas Research Network.","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell 32, 185\u2013203.e113 (2017).","journal-title":"Cancer Cell"},{"key":"67197_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/JP9.0000000000000109","volume":"5","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q. et al. Pancreatic ductal adenocarcinoma holds unique features to form an immunosuppressive microenvironment: a narrative review. J. Pancreatol. 5, 174\u2013185 (2022).","journal-title":"J. Pancreatol."},{"key":"67197_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/21541248.2023.2212573","volume":"14","author":"S Hodder","year":"2023","unstructured":"Hodder, S., Fox, M., Binti Ahmad Mokhtar, A. M., Mott, H. R. & Owen, D. ACKnowledging the role of the Activated-Cdc42 associated kinase (ACK) in regulating protein stability in cancer. Small GTPases 14, 14\u201325 (2023).","journal-title":"Small GTPases"},{"key":"67197_CR13","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1038\/onc.2014.350","volume":"34","author":"K Mahajan","year":"2015","unstructured":"Mahajan, K. & Mahajan, N. P. ACK1\/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers. Oncogene 34, 4162\u20134167 (2015).","journal-title":"Oncogene"},{"key":"67197_CR14","doi-asserted-by":"publisher","first-page":"15901","DOI":"10.1073\/pnas.0508014102","volume":"102","author":"EH van der Horst","year":"2005","unstructured":"van der Horst, E. H. et al. Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc. Natl. Acad. Sci. USA 102, 15901\u201315906 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67197_CR15","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ajpath.2011.12.028","volume":"180","author":"K Mahajan","year":"2012","unstructured":"Mahajan, K. et al. Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. Am. J. Pathol. 180, 1386\u20131393 (2012).","journal-title":"Am. J. Pathol."},{"key":"67197_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3389\/fonc.2020.01132","volume":"10","author":"J Zhu","year":"2020","unstructured":"Zhu, J. et al. Comprehensive Analysis of the Immune Implication of ACK1 Gene in Non-small Cell Lung Cancer. Front. Oncol. 10, 1132 (2020).","journal-title":"Front. Oncol."},{"key":"67197_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09165-w","volume":"22","author":"D Kong","year":"2022","unstructured":"Kong, D. et al. Identification of an ACK1\/TNK2-based prognostic signature for colon cancer to predict survival and inflammatory landscapes. BMC Cancer 22, 84 (2022).","journal-title":"BMC Cancer"},{"key":"67197_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34724-5","volume":"13","author":"D Sridaran","year":"2022","unstructured":"Sridaran, D. et al. Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance. Nat. Commun. 13, 6929 (2022).","journal-title":"Nat. Commun."},{"key":"67197_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","volume":"15","author":"A Singh","year":"2009","unstructured":"Singh, A. et al. A gene expression signature associated with \u201cK-Ras addiction\u201d reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489\u2013500 (2009).","journal-title":"Cancer Cell"},{"key":"67197_CR20","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin, J. et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat. Med. 28, 2171\u20132182 (2022).","journal-title":"Nat. Med."},{"key":"67197_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 619, 160\u2013166 (2023).","journal-title":"Nature"},{"key":"67197_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk0850","volume":"384","author":"JE Klomp","year":"2024","unstructured":"Klomp, J. E. et al. Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer. Science 384, eadk0850 (2024).","journal-title":"Science"},{"key":"67197_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk0775","volume":"384","author":"JA Klomp","year":"2024","unstructured":"Klomp, J. A. et al. Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. Science 384, eadk0775 (2024).","journal-title":"Science"},{"key":"67197_CR24","doi-asserted-by":"publisher","first-page":"i436","DOI":"10.1093\/bioinformatics\/btz363","volume":"35","author":"G Sturm","year":"2019","unstructured":"Sturm, G. et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics 35, i436\u2013i445 (2019).","journal-title":"Bioinformatics"},{"key":"67197_CR25","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1080\/15548627.2022.2103961","volume":"19","author":"S Chouhan","year":"2023","unstructured":"Chouhan, S. et al. TNK2\/ACK1-mediated phosphorylation of ATP5F1A (ATP synthase F1 subunit alpha) selectively augments survival of prostate cancer while engendering mitochondrial vulnerability. Autophagy 19, 1000\u20131025 (2023).","journal-title":"Autophagy"},{"key":"67197_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166690","volume":"1869","author":"W He","year":"2023","unstructured":"He, W. et al. Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors. Biochim. Biophys. Acta Mol. Basis Dis. 1869, 166690 (2023).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"67197_CR27","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ccell.2017.05.003","volume":"31","author":"K Mahajan","year":"2017","unstructured":"Mahajan, K. et al. ACK1\/TNK2 regulates histone H4 Tyr88-phosphorylation and AR gene expression in castration-resistant prostate cancer. Cancer Cell 31, 790\u2013803.e798 (2017).","journal-title":"Cancer Cell"},{"key":"67197_CR28","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1038\/s41388-023-02747-x","volume":"42","author":"M Sawant","year":"2023","unstructured":"Sawant, M. et al. Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4\/6 inhibitor. Oncogene 42, 2263\u20132277 (2023).","journal-title":"Oncogene"},{"key":"67197_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/bs.acr.2019.01.004","volume":"142","author":"JR Sedy","year":"2019","unstructured":"Sedy, J. R. & Ramezani-Rad, P. HVEM network signaling in cancer. Adv. Cancer Res 142, 145\u2013186 (2019).","journal-title":"Adv. Cancer Res"},{"key":"67197_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1600-065X.2011.01064.x","volume":"244","author":"MW Steinberg","year":"2011","unstructured":"Steinberg, M. W., Cheung, T. C. & Ware, C. F. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol. Rev. 244, 169\u2013187 (2011).","journal-title":"Immunol. Rev."},{"key":"67197_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).","journal-title":"Nat. Commun."},{"key":"67197_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ccell.2021.12.009","volume":"40","author":"E Limagne","year":"2022","unstructured":"Limagne, E. et al. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. Cancer Cell 40, 136\u2013152 e112 (2022).","journal-title":"Cancer Cell"},{"key":"67197_CR33","doi-asserted-by":"publisher","first-page":"116231","DOI":"10.1016\/j.ejmech.2024.116231","volume":"268","author":"K Wojciechowicz","year":"2024","unstructured":"Wojciechowicz, K., Spodzieja, M. & Wardowska, A. The BTLA-HVEM complex - the future of cancer immunotherapy. Eur. J. Med. Chem. 268, 116231 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"67197_CR34","doi-asserted-by":"publisher","first-page":"e9646","DOI":"10.1371\/journal.pone.0009646","volume":"5","author":"K Mahajan","year":"2010","unstructured":"Mahajan, K. et al. Ack1 mediated AKT\/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One 5, e9646 (2010).","journal-title":"PLoS One"},{"key":"67197_CR35","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.18632\/oncotarget.13579","volume":"8","author":"X Wu","year":"2017","unstructured":"Wu, X. et al. The non-receptor tyrosine kinase TNK2\/ACK1 is a novel therapeutic target in triple negative breast cancer. Oncotarget 8, 2971\u20132983 (2017).","journal-title":"Oncotarget"},{"key":"67197_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.semcancer.2019.10.002","volume":"60","author":"Y Verhoeven","year":"2020","unstructured":"Verhoeven, Y. et al. The potential and controversy of targeting STAT family members in cancer. Semin. Cancer Biol. 60, 41\u201356 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"67197_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10020-023-00602-z","volume":"29","author":"J Zhu","year":"2023","unstructured":"Zhu, J. et al. Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1. Mol. Med. 29, 6 (2023).","journal-title":"Mol. Med."},{"key":"67197_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.864995","volume":"13","author":"L Jing","year":"2022","unstructured":"Jing, L. et al. ACK1 contributes to the pathogenesis of inflammation and autoimmunity by promoting the activation of TLR signaling pathways. Front. Immunol. 13, 864995 (2022).","journal-title":"Front. Immunol."},{"key":"67197_CR39","doi-asserted-by":"crossref","unstructured":"Sorkina, T., Ma, S., Larsen, M. B., Watkins, S. C. & Sorkin, A. Small molecule induced oligomerization, clustering and clathrin-independent endocytosis of the dopamine transporter. Elife 7, e32293 (2018).","DOI":"10.7554\/eLife.32293"},{"key":"67197_CR40","doi-asserted-by":"crossref","unstructured":"Sridaran, D. & Mahajan, N. P. ACK1\/TNK2 kinase: molecular mechanisms and emerging cancer therapeutics. Trends Pharmacol. Sci. 46, 62\u201377 (2025).","DOI":"10.1016\/j.tips.2024.11.006"},{"key":"67197_CR41","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padron","year":"2022","unstructured":"Padron, L. J. et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med. 28, 1167\u20131177 (2022).","journal-title":"Nat. Med."},{"key":"67197_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32591-8","volume":"13","author":"DJ Renouf","year":"2022","unstructured":"Renouf, D. J. et al. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat. Commun. 13, 5020 (2022).","journal-title":"Nat. Commun."},{"key":"67197_CR43","doi-asserted-by":"publisher","first-page":"10605","DOI":"10.1074\/jbc.M109.060459","volume":"285","author":"V Prieto-Echague","year":"2010","unstructured":"Prieto-Echague, V., Gucwa, A., Craddock, B. P., Brown, D. A. & Miller, W. T. Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1. J. Biol. Chem. 285, 10605\u201310615 (2010).","journal-title":"J. Biol. Chem."},{"key":"67197_CR44","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M. & Maitra, A. Pancreatic cancer: advances and challenges. Cell 186, 1729\u20131754 (2023).","journal-title":"Cell"},{"key":"67197_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","volume":"17","author":"L Buscail","year":"2020","unstructured":"Buscail, L., Bournet, B. & Cordelier, P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 153\u2013168 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"67197_CR46","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/0008-5472.CAN-23-2504","volume":"84","author":"V Kumarasamy","year":"2024","unstructured":"Kumarasamy, V. et al. The extracellular niche and tumor microenvironment enhance KRAS inhibitor efficacy in pancreatic cancer. Cancer Res. 84, 1115\u20131132 (2024).","journal-title":"Cancer Res."},{"key":"67197_CR47","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med. 30, 531\u2013542 (2024).","journal-title":"Nat. Med."},{"key":"67197_CR48","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.18632\/aging.202408","volume":"13","author":"J Zhu","year":"2021","unstructured":"Zhu, J. et al. Identification of downstream signaling cascades of ACK1 and prognostic classifiers in non-small cell lung cancer. Aging 13, 4482\u20134502 (2021).","journal-title":"Aging"},{"key":"67197_CR49","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.immuni.2016.04.019","volume":"44","author":"LK Ward-Kavanagh","year":"2016","unstructured":"Ward-Kavanagh, L. K., Lin, W. W., Sedy, J. R. & Ware, C. F. The TNF receptor superfamily in co-stimulating and co-inhibitory responses. Immunity 44, 1005\u20131019 (2016).","journal-title":"Immunity"},{"key":"67197_CR50","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41423-019-0241-1","volume":"16","author":"JI Rodriguez-Barbosa","year":"2019","unstructured":"Rodriguez-Barbosa, J. I. et al. HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT. Cell Mol. Immunol. 16, 679\u2013682 (2019).","journal-title":"Cell Mol. Immunol."},{"key":"67197_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01845-4","volume":"22","author":"C Sordo-Bahamonde","year":"2023","unstructured":"Sordo-Bahamonde, C. et al. Beyond the anti-PD-1\/PD-L1 era: promising role of the BTLA\/HVEM axis as a future target for cancer immunotherapy. Mol. Cancer 22, 142 (2023).","journal-title":"Mol. Cancer"},{"key":"67197_CR52","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/0008-5472.CAN-11-2637","volume":"72","author":"J Fourcade","year":"2012","unstructured":"Fourcade, J. et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72, 887\u2013896 (2012).","journal-title":"Cancer Res."},{"key":"67197_CR53","doi-asserted-by":"crossref","unstructured":"Yang, Y. et al. Targeting the STAT5A\/IDO1 axis overcomes radioresistance and reverses the immunosuppressive tumor microenvironment in NSCLC. Int. J. Oncol. 62, 12 (2023).","DOI":"10.3892\/ijo.2022.5460"},{"key":"67197_CR54","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1126\/science.283.5399.222","volume":"283","author":"T Welte","year":"1999","unstructured":"Welte, T. et al. STAT5 interaction with the T cell receptor complex and stimulation of T cell proliferation. Science 283, 222\u2013225 (1999).","journal-title":"Science"},{"key":"67197_CR55","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1182\/blood.V95.4.1370.004k29_1370_1377","volume":"95","author":"S Kagami","year":"2000","unstructured":"Kagami, S. et al. Both stat5a and stat5b are required for antigen-induced eosinophil and T-cell recruitment into the tissue. Blood 95, 1370\u20131377 (2000).","journal-title":"Blood"},{"key":"67197_CR56","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood.V97.8.2358","volume":"97","author":"S Kagami","year":"2001","unstructured":"Kagami, S. et al. Stat5a regulates T helper cell differentiation by several distinct mechanisms. Blood 97, 2358\u20132365 (2001).","journal-title":"Blood"},{"key":"67197_CR57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-022-00833-x","volume":"23","author":"D Arcia-Anaya","year":"2023","unstructured":"Arcia-Anaya, D. & Elliott, T. STAT5A antagonizes TOX in CD8(+) T cell exhaustion. Nat. Rev. Immunol. 23, 73 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"67197_CR58","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13046-023-02814-x","volume":"42","author":"C She","year":"2023","unstructured":"She, C. et al. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP\/PERK\/eIF2alpha-axis-mediated endoplasmic reticulum stress. J. Exp. Clin. Cancer Res. 42, 238 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"67197_CR59","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/j.bbadis.2018.05.013","volume":"1864","author":"C Wu","year":"2018","unstructured":"Wu, C. et al. Epigenetic dysregulation of ZEB1 is involved in LMO2-promoted T-cell acute lymphoblastic leukaemia leukaemogenesis. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 2511\u20132525 (2018).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"67197_CR60","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739\u2013W743 (2022).","journal-title":"Nucleic Acids Res."},{"key":"67197_CR61","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543\u2013D552 (2022).","journal-title":"Nucleic Acids Res."},{"key":"67197_CR62","doi-asserted-by":"crossref","unstructured":"Zhang \u5f20\u601d\u601d, S. et al. The GSA family in 2025: a broadened sharing platform for multi-omics and multimodal data. Genom. Proteomics Bioinform. 23, qzaf072 (2025).","DOI":"10.1093\/gpbjnl\/qzaf072"},{"key":"67197_CR63","unstructured":"CNCB-NGDC Members and Partners. Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2025. Nucleic Acids Res. 53, D30\u2013D44 (2025)."},{"key":"67197_CR64","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.gpb.2021.08.001","volume":"19","author":"T Chen","year":"2021","unstructured":"Chen, T. et al. The genome sequence archive family: toward explosive data growth and diverse data types. Genom. Proteom. Bioinforma. 19, 578\u2013583 (2021).","journal-title":"Genom. Proteom. Bioinforma."},{"key":"67197_CR65","unstructured":"CNCB-NGDC Members and Partners. Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2024. Nucleic Acids Res. 52, D18\u2013D32 (2024)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67197-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67197-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67197-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:06:01Z","timestamp":1768403161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67197-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67197"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67197-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"12 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"512"}}